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Abstract
Background: Evidence suggests that vagal nerve activity may play a role in sleep apnea induction. In anesthetized
rats, dronabinol, a cannabinoid (CB) receptor agonist, injected into the nodose ganglia attenuates reflex apnea and
increases genioglossus activity, and reflex apnea attenuation is blocked by systemic pre-treatment with cannabinoid
type 1 and/or type 2 receptor antagonists. However, it is unclear whether dronabinol has similar effects in the
central nervous system; CB receptors are widely distributed in the brain, especially on neuronal circuitry important
for respiration and upper airway activation. Here, we examine the effects of intracerebroventricular (ICV) injection of
dronabinol on serotonin (5-HT)-induced apnea.
Methods: Adult male Sprague-Dawley rats were anesthetized and instrumented with bilateral electrodes to
monitor genioglossi EMG and with a piezoelectric strain gauge to monitor respiratory pattern. Serotonin was
intravenously infused into a femoral vein to induce reflex apnea. After baseline recordings, rats were placed in a
stereotaxic apparatus. A unilateral osteotomy was made to allow access for injection to the right lateral ventricle,
and the dura were carefully removed. Dronabinol (100, 10, 1, or 0.1 μg/3 μl DMSO) or control (3 μl DMSO) was
injected into the right lateral ventricle and 5-HT infusion was repeated. Data (mean ± SEM) were analyzed using a
mixed model analysis with a repeated/fixed measure.
Results: There was no main effect in 5-HT-induced apnea or breath duration, or in breath instability, between ICV
dronabinol injected and ICV vehicle control injected groups. Moreover, there was no main effect in phasic or tonic
genioglossus activity between ICV dronabinol injected and ICV vehicle control injected groups.
Conclusion: Our data show that ICV injection of dronabinol did not decrease 5-HT-induced apneas, and did not
increase genioglossus activity. This in contrast to published results of dronabinol’s effect on apnea via the vagus
nerve. Our results suggest that the effects of dronabinol on reflex apneas are peripherally mediated via suppression
of vagal nerve activity.
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Background
Obstructive sleep apnea (OSA), characterized by a cessa-
tion of breathing produced by a narrowed or collapsed
upper airway, represents a significant public health risk
[1, 2]. Current OSA prevalence estimates indicate that
14 % of American men and 5 % of American women
suffer from OSA, and that those estimates are rising [1].
More importantly, there are strong associations between
OSA and other diseases, such as type 2 diabetes, hyper-
tension, stroke, and coronary heart disease [3–5]. The
“gold standard” of OSA treatment is to splint open the
upper airway via continuous positive air pressure; how-
ever, treatment tolerance is low and patients do not ad-
here to treatment despite obvious health benefits [2].
Safe and effective pharmacological treatments for OSA
remain to be identified, and such efforts have been lim-
ited by incomplete knowledge of the central and periph-
eral neural mechanisms controlling respiration during
sleep [2, 6]. Recently, activating the inhibitory Gi/o-associ-
ated cannabinoid (CB) receptors have been proposed as
novel pharmacological intervention to treat OSA [7, 8].
The endocannabinoid system, associated with canna-
binoid type 1 (CB1) and cannabinoid type 2 (CB2)
receptors located on peripheral nerves and central neu-
rons, can be targeted therapeutically to modify disease
states [9, 10]. Dronabinol, a synthetic version of Δ9-
THC, is a FDA-approved CB1 and CB2 receptor agonist
used to suppress chemotherapy-induced nausea and
stimulate appetite in AIDS patients [11]. Dronabinol,
when administered to patients with OSA [12], or to rats
chronically-instrumented to measure respiration during
sleep [13], decreased apneas. The mechanism of drona-
binol’s effect in decreasing apnea propensity appeared to
be, in part, due to the activation of both CB1 and CB2
receptors located on nodose ganglia of the vagus nerves
[14, 15], which transmit vital information from the lungs
to the brainstem, contributing to reflex responses regu-
lating: tidal volume, respiratory frequency, augmented
breaths and bronchoconstriction [16, 17]. In a well-
established model of vagally-mediated reflex apnea [18],
dronabinol injected into nodose ganglia attenuated ap-
neas [15]. Antagonism of CB1, CB2, or both reversed
dronabinol’s attenuation of apneas [14]. More import-
antly, dronabinol also increased phasic upper airway ac-
tivity via activation of CB receptors at the nodose
ganglia [14, 15]. Though recent evidence confirms the
role the vagus nerve plays in apnea propensity [14, 15,
19–21], less is known about the role that central CB
receptors have in apnea induction or suppression. Dro-
nabinol is highly lipophilic and readily crosses the blood-
brain barrier into the central nervous system [22], where
CB receptors are widely distributed [23, 24] [10], including
brain areas vital to respiratory control [23, 25–28]. Com-
plicating the issue further is that activating central CB
receptors can inhibit evoked release of excitatory or in-
hibitory neurotransmitters [29], thereby inhibiting or dis-
inhibiting neuronal activity [9, 30]. It is unknown if
central versus peripheral administration of a CB agonist
would have similar or dissimilar effects on respiration.
Therefore, it is important to understand dronabinol’s glo-
bal effects on the central nervous system without activat-
ing CB receptors in the peripheral nervous system.
Here, we hypothesized that global central administra-
tion via intracerebroventricular (ICV) injection of drona-




Thirty adult male Sprague-Dawley rats (275–300 g) were
purchased from Harlan Laboratories (Indianapolis, IN,
USA), housed in duplicate, maintained on a 12:12 light:-
dark cycle at 22 ± 0.5 °C, and allowed ad libitum access
to food and water. All animal procedures and protocols
were approved by the Institutional Animal Care and Use
Committee of the University of Illinois at Chicago
(Protocol no.: 11–217/14–159).
Acute ICV injection experiment paradigm
Rats (N = 30) were anesthetized (IP ketamine:xylazine
100:10 mg/kg; IP redosing 100:5 mg/kg; surgical plane of
anesthesia was monitored by toe pinch) and instru-
mented with bilateral electrodes to monitor genioglossus
EMG (EMGgg; 1 mm lateral to the midline) and with a
piezoelectric strain gauge to monitor respiratory pattern.
The femoral vein was cannulated for 5-HT (12.5 μg/kg;
MP Biomedicals, Solon, OH, USA) in PBS (pH 7.4;
0.35 ml/kg) infusions via an infusion pump (63 ml/h;
KD Scientific, Holliston, MA, USA) to induce reflex ap-
neas (repeated a minimum of two times). After baseline
recordings (N = 30), the head of the rat was mounted in
a stereotaxic frame, and dorsal craniotomy was per-
formed to allow for right ICV injections of dronabinol
(10 mg capsules, Marinol, Abbvie Inc., North Chicago,
IL, USA) at various concentrations (100, 10, 1, or 0.1 μg/
3 μl DMSO; N = 6 for each concentration) or vehicle
control (3 μl DMSO; N = 6) using a 28 gauge needle. Dro-
nabinol ICV doses were chosen based on other physio-
logical effects of various Δ9-THC ICV doses [31–34].
After ICV injections over a minimum 3 min period, 5-HT
infusions were performed again to induce reflex apneas
(repeated a minimum of two times).
Data recording and processing
Data recording and processing have been described before
[14, 15]. Briefly, during EMGgg and respiratory data ac-
quisition, signals were amplified and band-passed filtered
(10–240 Hz and 1–10 Hz, respectively; CyberAmp 380,
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Axon Instruments, Sunnyvale, CA, USA), digitized at
500 Hz (Data Acquisition Subsystems, DataWave Tech-
nologies, Loveland, CO, USA), and recorded and saved
using SciWorks Experimenter software (DataWave Tech-
nologies, Loveland, CO, USA). After recording, EMGgg
data were rectified and smoothed (time constant of
100 ms) using Spike2 software (Cambridge Electronic De-
sign, Cambridge, England). Tonic EMGgg was defined as
the nadir of smoothed expiratory genioglossus activity.
Phasic EMGgg was defined as the peak of smoothed in-
spiratory genioglossus activity minus tonic EMGgg.
EMGgg signals after ICV injections were normalized by
dividing by EMGgg signals recorded before ICV injections,
and are reported as arbitrary units (a.u.). Breath durations,
and phasic and tonic EMGgg amplitudes were averaged
from 5 previous breaths before IV 5-HT infusion; this was
repeated a minimum of two times and averaged. Apnea du-
rations were defined as the average of the longest breath
durations lasting at least 2.5 seconds [13] within 30 seconds
following IV 5-HT infusion. For measurement of respira-
tory instability [35], coefficient of variation was calculated
for 30 breath durations before and after injection of 5-HT.
Statistical analysis
Data (mean ± SEM) were analyzed using IBM SPSS
Statistics 22 (New York, NY, USA) mixed model analysis
with a repeated/fixed measure (ICV treatment) or two-
way repeated/fixed measure (time × ICV treatment)
followed by post hoc multiple comparison tests with
Sidak’s correction if there was a significant main effect.
Repeated covariance structure was chosen according to
the best-fit Schwarz’s Bayesian information criterion.
Statistical significance was set at p < 0.05.
Results
Reflex apneas induced via IV infusion of 5-HT were
conducted in rats before and after ICV injections of vari-
ous concentrations of dronabinol (Fig. 1). Also, breath
duration, coefficient of breath durations, and phasic and
tonic genioglossus activity were quantified before and
after ICV injections of various concentrations of drona-
binol (Figs. 2, 3, and 4, respectively).
At baseline (before ICV injections), IV 5-HT infu-
sion produced reflex apneas lasting 7.29 ± 0.75 seconds
(N = 30). ICV injections of 100 μg (11.80 ± 2.66 seconds,
N = 6), 10 μg (7.73 ± 0.85 seconds, N = 6), 1 μg (7.48 ±
0.87 seconds, N = 6), or 0.1 μg (9.67 ± 1.46 seconds, N = 6)
of dronabinol, or injection of vehicle (DMSO; 7.79 ±
0.93 seconds, N = 6) did not significantly (F5, 35.6 = 1.90,
p = 0.12 for main effect of “treatment”) alter apnea
durations compared to baseline (Fig. 1).
Breath durations were averaged from 5 breaths prior
to 5-HT-induced apneas. Average breath duration before
ICV injections was 0.89 ± 0.03 seconds (N = 30), and was
not significantly (F5, 32.7 = 1.89, p = 0.12) altered by
100 μg (0.84 ± 0.06 seconds, N = 6), 10 μg (0.84 ±
0.08 seconds, N = 6), 1 μg (0.75 ± 0.03 seconds, N = 6), or
0.1 μg (0.86 ± 0.06 seconds, N = 6) ICV injection of dro-
nabinol, or ICV injection of vehicle (DMSO; 0.99 ±
0.11 seconds, N = 6; Fig. 2). Coefficient of variation of 30
breath durations before (pre) and after (post) 5-HT infu-
sion was quantified as a measurement of respiratory in-
stability (Fig. 3) [35]. There was no ICV treatment main
effect (F5, 11.0 = 1.03, p = 0.45) or interaction between
ICV treatment and time (F5, 11.0 = 1.01, p = 0.46). There
was a main effect of time (F1, 14.5 = 87.7, p < 0.01);
Fig. 1 Apnea duration quantified from acute 5-HT-induced apnea
experiments before (baseline; N = 30) and after ICV injections of
various concentrations of dronabinol (100, 10, 1 or 0.1 μg; N = 6 for
each dose) or vehicle (DMSO; N = 6). ICV injections of dronabinol at
any concentration did not significantly (p = 0.19) attenuate reflex
apneas. Data (mean ± SEM) were analyzed using mixed model
analysis with a repeated/fixed measure (ICV treatment)
Fig. 2 Breath duration quantified prior to 5-HT infusion before
(baseline; N = 30) and after ICV injections of various concentrations
of dronabinol (100, 10, 1 or 0.1 μg; N = 6 for each dose) or vehicle
(DMSO; N = 6). There were no significantly (p = 0.12) differences in
breath duration in the treatment groups. Data (mean ± SEM) were
analyzed using mixed model analysis with a repeated/fixed measure
(ICV treatment)
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breathing was more unstable following 5-HT infusion
compared to before infusion (p < 0.01; Fig. 3).
Genioglossus activity was measured at the start of in-
spiration (Phasic EMGgg) and at the end of expiration
(tonic EMGgg) prior to reflex apneas (Fig. 4). ICV Injec-
tions of 100 μg (0.89 ± 0.28 a.u., N = 6), 10 μg (1.17 ± 0.41
a.u., N = 6), 1 μg (0.59 ± 0.12 a.u., N = 6), or 0.1 μg (0.93 ±
0.24 a.u., N = 6) of dronabinol, or injection of vehicle
(DMSO; 0.63 ± 0.11 a.u., N = 6) did not significantly
(F4, 9.50 = 0.94, p = 0.48 for main effect of “treatment”)
alter phasic EMGgg (Fig. 4a). Similarly, ICV injections
of 100 μg (0.97 ± 0.13 a.u., N = 6), 10 μg (1.46 ±
0.20 a.u., N = 6), 1 μg (1.33 ± 0.45 a.u., N = 6), or
0.1 μg (1.23 ± 0.29 a.u., N = 6) of dronabinol, or injec-
tion of vehicle (DMSO; 1.35 ± 0.46 a.u., N = 6) did not
significantly (F4, 7.96 = 1.22, p = 0.37 for main effect of
“treatment”) alter tonic EMGgg (Fig. 4b).
Discussion
With the increasing prevalence [1], comorbidity with
other diseases [3–5], and a lack of tolerable and effective
treatment options [2, 6], OSA is a significant health
problem. An impediment to effective treatments of OSA
is insufficient knowledge of peripheral and central neural
mechanisms of respiratory control, especially during
sleep. Though we have shown previously that modula-
tion of vagal afferents via activation of CB receptors lo-
cated on nodose ganglion neurons can attenuate reflex
apneas [14, 15], it was uncertain what role central CB
receptors play in respiratory pattern control. Here we
show that ICV injection of dronabinol, a non-specific
agonist of CB1 and CB2 receptors, does not attenuate
peripherally-induced reflex apneas.
Vagal afferent neurons, which relay important infor-
mation about respiratory drive and upper airway muscle
tone [16, 17, 36], provide input to the excitatory or in-
hibitory neurons located in nucleus of the solitary tract
(NTS) [37, 38]. The NTS projects to the respiratory
centers of the brainstem, including the hypoglossal nu-
cleus (XII) and the rostral ventrolateral medulla (RVLM)
[36, 39]. The NTS contains a variety of neuronal popula-
tions that fire at distinct points in the expiratory-
inspiratory phases of breathing [40]. Reflex apneas are
Fig. 3 Coefficient of 30 breath durations (%) quantified prior (pre) to
and after (post) 5-HT infusion before (baseline) and after ICV injections
of various concentrations of dronabinol (100, 10, 1 or 0.1 μg;
N = 6 for each dose) or vehicle (DMSO; N = 6). There were no
significant differences in ICV treatment (P = 0.45) or interaction
between time and ICV treatment (p = 0.46). However, there was a main
effect of time (p < 0.01), with post hoc analysis showing a significant
increase in respiratory instability after 5-HT infusion (p < 0.01). Data
(mean ± SEM) were analyzed using mixed model analysis with a two-
way repeated/fixed measure (time × ICV treatment)
Fig. 4 Phasic (a) and tonic (b) genioglossus electrogram amplitude (arbitrary units, a.u.; dotted line corresponds to baseline EMGgg) quantified
after ICV injections of various concentrations of dronabinol (100, 10, 1 or 0.1 μg; N = 6 for each dose) or vehicle (DMSO; N = 6). There were no
significant differences in phasic (p = 0.48) or tonic (p = 0.37) EMGgg in the treatment groups. Data (mean ± SEM) were analyzed using mixed
model analysis with a repeated/fixed measure (ICV treatment)
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induced peripherally via the vagus nerve by pharmaco-
logically activating excitatory receptors located on nodose
ganglia, or by mechanically activating stretch receptors lo-
cated in the lung [16, 41]. Reflex apneas are also induced
“downstream” by activation of glutamatergic receptors in
the NTS [42–45]. Conversely, vagally-induced apnea can
be reversed by microinjection of a GABA agonist [46], or
a glutamatergic NMDA antagonist [45], into the NTS.
Vagal afferents also synapse in regions of the NTS that
modulate sympathetic activity, with activation of vagal af-
ferents not only inducing apnea, but decreasing heart rate
and blood pressure [41]. This trifecta of responses, known
as the Bezold-Jarisch reflex, is modulated by different re-
gions of the NTS, and these regions, when activated or
inhibited, induce variable responses in blood pressure,
heart rate, and breathing [45–47]. The NTS contains
both CB1 and CB2 receptors that, when activated, in-
hibit or promote NTS activity, and attenuate other
vagally-mediated behaviors [26, 27, 48–51]. CB1 activa-
tion decreases glutamate release in the NTS [51], thus
CB1 activation would have the effect of suppressing ap-
neas. CB1 activation also disinhibits second order NTS
neurons by pre-synaptically decreasing release of
GABA [51–53], thus CB1 activation would have the op-
posite effect of potentiating apneas. It might be plaus-
ible that the dual effects of CB1 activation occurred,
with the consequence of neither suppressing nor po-
tentiating apneas.
Moreover, the XII, which modulates the phasic and
tonic activation of the genioglossus muscle [36], also
contains CB1 receptors [23, 25, 28, 54, 55], of which the
physiologic role is unclear. CB1 activation in the XII is
known to disinhibit XII by preventing release of glycine,
an inhibitory neurotransmitter [25, 54]. In fact, a CB
agonist microinjected in the XII activated the genioglos-
sus in awake, but not sleeping, rats [55]. A recent report
showed cardiorespiratory anomalies, including unstable
breathing and apneas, in CB1 knockout mice [56]. We
hypothesized that the activation of CB receptors located at
crucial respiratory centers in the brainstem would modu-
late reflex apneas and increase genioglossus activity; how-
ever, we saw no effect of a centrally-administered CB
agonist, dronabinol.
The present work focused on global activation of CB
receptors located in the brain, which mimicked patients
undergoing dronabinol treatment [12], and did not eluci-
date any specific local effects of the respiratory centers
of the brainstem. Due to the variability of Bezold-Jarisch
reflex responses to NTS activation or inhibition, and the
location of CB receptors on both excitatory and inhibi-
tory neurons of the NTS, it is possible that non-specific
and global activation of central CB receptors via ICV
injection of dronabinol led to multiple and potentially
opposing responses, masking any specific local effects.
Therefore no physiologic response was observed. For ex-
ample, Padley et al. induced apnea by microinjecting a
CB1 agonist centrally into the RVLM, which sends pro-
jections to inhibitory neurons located in the respiratory
centers of the brainstem [39]. Also, injection of CBs per-
ipherally in the nodose ganglia increased genioglossus
activity, presumably through disinhibition of parasympa-
thetic input into respiratory centers of the brain [15].
Carley et al. showed respiratory stability with intraperi-
toneal injections of dronabinol, which would involve
both peripheral and central CB receptors [13]. Moreover,
low and high doses of CBs are known to have biphasic
effects [31, 57]; however, we saw no changes in apnea re-
sponse at low or high doses of dronabinol. Since CB re-
ceptors are widely distributed in the brain, on both
excitatory and inhibitory neurons, and are activated dif-
ferentially by different concentrations of CBs, specific
microinjections in the NTS or XII will need to be com-
pleted to see if CBs have any effect on breathing and
genioglossus activity in rats.
Conclusions
In conclusion, we show that ICV injections of dronabi-
nol, a non-specific CB agonist, had no effect on 5-HT-
induced reflex apnea, and had no effect on genioglossus
activity. These results suggest that central CB receptors
have a minimal or no effect on breathing when activated
globally; however, there might be specific local effects of
CBs due to the diverse population of neuronal inputs
and outputs of the NTS. Previous work showing
stabilization of breathing from CBs might be derived
from activation of CB receptors located on peripheral
nerves [13–15], suggesting that pharmacotherapies tar-
geting only peripheral CB receptors for OSA treatment
might be sufficient. Future work will concentrate on elu-
cidating specific local effects of CBs on breathing in the
NTS and XII.
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